24,348 Shares in Merck & Co., Inc. (MRK) Acquired by Valeo Financial Advisors LLC

Valeo Financial Advisors LLC purchased a new stake in Merck & Co., Inc. (NYSE:MRK) in the 2nd quarter, HoldingsChannel reports. The fund purchased 24,348 shares of the company’s stock, valued at approximately $1,624,000.

A number of other institutional investors have also recently bought and sold shares of MRK. Cobblestone Capital Advisors LLC NY raised its holdings in shares of Merck & Co., Inc. by 0.4% in the 2nd quarter. Cobblestone Capital Advisors LLC NY now owns 187,080 shares of the company’s stock worth $11,356,000 after buying an additional 774 shares in the last quarter. Associated Banc Corp raised its holdings in shares of Merck & Co., Inc. by 0.3% in the 2nd quarter. Associated Banc Corp now owns 251,933 shares of the company’s stock worth $15,293,000 after buying an additional 776 shares in the last quarter. Twin Capital Management Inc. raised its holdings in shares of Merck & Co., Inc. by 0.3% in the 2nd quarter. Twin Capital Management Inc. now owns 269,930 shares of the company’s stock worth $16,385,000 after buying an additional 780 shares in the last quarter. Checchi Capital Advisers LLC raised its holdings in shares of Merck & Co., Inc. by 3.0% in the 2nd quarter. Checchi Capital Advisers LLC now owns 26,914 shares of the company’s stock worth $1,634,000 after buying an additional 792 shares in the last quarter. Finally, Nicollet Investment Management Inc. raised its holdings in shares of Merck & Co., Inc. by 2.2% in the 2nd quarter. Nicollet Investment Management Inc. now owns 36,898 shares of the company’s stock worth $2,240,000 after buying an additional 805 shares in the last quarter. 72.18% of the stock is owned by hedge funds and other institutional investors.

MRK has been the subject of a number of recent research reports. Jefferies Financial Group reissued a “hold” rating and issued a $59.00 target price on shares of Merck & Co., Inc. in a report on Sunday, July 15th. BMO Capital Markets restated a “buy” rating and set a $70.00 price target on shares of Merck & Co., Inc. in a research report on Sunday, July 22nd. Bank of America increased their price target on Merck & Co., Inc. from $70.00 to $74.00 and gave the stock a “buy” rating in a research report on Monday, July 30th. SunTrust Banks restated a “buy” rating and set a $77.00 price target on shares of Merck & Co., Inc. in a research report on Thursday, August 16th. Finally, Morgan Stanley set a $74.00 price target on Merck & Co., Inc. and gave the stock a “buy” rating in a research report on Thursday, August 23rd. Six investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $70.24.

NYSE MRK opened at $71.22 on Wednesday. The company has a market cap of $191.27 billion, a P/E ratio of 17.89, a price-to-earnings-growth ratio of 2.22 and a beta of 0.81. Merck & Co., Inc. has a one year low of $52.83 and a one year high of $72.89. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.04 and a current ratio of 1.33.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Friday, July 27th. The company reported $1.06 EPS for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.03. The business had revenue of $10.47 billion for the quarter, compared to analyst estimates of $10.28 billion. Merck & Co., Inc. had a return on equity of 32.68% and a net margin of 3.67%. Merck & Co., Inc.’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the prior year, the company earned $1.01 EPS. Analysts forecast that Merck & Co., Inc. will post 4.27 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 5th. Shareholders of record on Monday, September 17th were given a $0.48 dividend. The ex-dividend date of this dividend was Friday, September 14th. This represents a $1.92 dividend on an annualized basis and a yield of 2.70%. Merck & Co., Inc.’s payout ratio is 48.24%.

In other Merck & Co., Inc. news, Chairman Kenneth C. Frazier sold 279,850 shares of the stock in a transaction on Tuesday, October 2nd. The stock was sold at an average price of $72.07, for a total value of $20,168,789.50. Following the transaction, the chairman now directly owns 971,800 shares in the company, valued at approximately $70,037,626. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Kenneth C. Frazier sold 228,091 shares of the stock in a transaction on Tuesday, July 31st. The shares were sold at an average price of $65.00, for a total value of $14,825,915.00. Following the completion of the transaction, the chairman now owns 938,788 shares in the company, valued at $61,021,220. The disclosure for this sale can be found here. Insiders sold a total of 929,360 shares of company stock worth $64,370,599 over the last quarter. Corporate insiders own 0.32% of the company’s stock.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

See Also: Growth Stocks, What They Are, What They Are Not

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply